uniQure vs Scynexis
QURE and SCYX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How QURE and SCYX compare
uniQure is the larger company, worth 52 times as much as Scynexis ($1.5B against $29.0M).
Scynexis grew revenue faster over the last twelve months (490% versus 30.2% for uniQure).
Scynexis keeps more of each dollar of sales as profit, with a net margin of −53.3% compared with −1351% at uniQure.
Scynexis scores higher on the StockData Score (13 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | QURE | SCYX |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $29.0M |
| Share price | $21.88 | $2.91 |
| Change, 1 year | −27.9% | −38.4% |
| Change, 5 years | −24.1% | −95.1% |
| Beta (5Y) | 3.07 | 1.56 |
| Employees | 221 | 18 |
| StockData Score | ||
| Total score | 4 | 13 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 | 2 |
| Performance score | 0 | 3 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 81.3× | 1.5× (better) |
| P/B | 4.7× | 0.4× (better) |
| FCF yield | −10.6% | – |
| Fair value | $6.38 | $10.10 |
| Margin of safety | −243% | 71.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 30.2% | 490% (better) |
| Revenue growth, 5Y average | −15.6% | – |
| Profitability | ||
| Gross margin | 92.5% | – |
| Operating margin | −1072% | −118% (better) |
| Net margin | −1351% | −53.3% (better) |
| FCF margin | −865% | – |
| Return on equity | −158% | −18.4% (better) |
| Financial health | ||
| Debt / equity | 0.15 (better) | 0.00 |
| Interest coverage | −3.4× | – |
| Current ratio | 10.01 (better) | 9.65 |
| Altman Z-score | −0.44 (better) | −5.22 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 96.0% | 51.7% |
| Held by insiders | 2.1% | 24.8% |
| Insider net buying, 12 months | −$20.2M | – |
| Short interest, % of float | 12.5% | 6.0% |
Go deeper
- QURE stock overview
- QURE income statement
- QURE valuation and score
- SCYX stock overview
- SCYX income statement
- SCYX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.